Aspire Biopharma dismisses auditor Bush, appoints Turner Stone; gets $1M funding tranche

Aspire Biopharma Holdings, Inc.

Dismissed Bush & Associates CPA as independent auditor effective Sept 22, 2025; 2024 audit included going concern explanatory paragraph.
Appointed Turner Stone & Co. as new independent auditor for FY 2025, effective Sept 22, 2025.
No disagreements with Bush; material weaknesses in internal control over financial reporting were disclosed.
Received $1M second tranche funding under Securities Purchase Agreement for notes with aggregate principal $9.6875M.

item 3.02item 4.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.